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Abstract  
Background Patients with systemic lupus 
erythematosus (SLE) and systemic sclerosis (SSc), 
have to cope with lifelong disease manifestation and 
impaired physical function. Limited physical activities 
along the disease will affect their quality of life (QoL). 
The QoL is recognized as an important factor of 
treatment strategy. This study aims to compare the 
quality of life of patient with SLE and SSc.  
Method This study was a cross-sectional study and 
conducted in rheumatology outpatient clinic of Hasan 
Sadikin Hospital Bandung, Indonesia from January 2015 
until March 2017. The respondents were patients 
diagnosed as SLE and SSc who regularly visit 
rheumatology outpatient clinic. Respondents were asked 
to complete the Short Form-36 (SF-36). Baseline 
characteristics, including age, gender, and duration of 
disease, were collected during the visit. The Mann-
Whitney U test was used to analyze the comparison. 
Result There were 242 patients who completed the SF-
36 questionnaires, consisted of 193 SLE patients and 49 
SSc patients. SLE patients were slightly younger and 
had a longer duration of disease compared to SSc. The 
SF-36 Physical Component Summary (PCS) score was 
significantly higher on SLE patients (40.6 vs 40.4, p =  
0.0001), but the mean of Mental Component 
Summary (MCS) score was similar among both 
diseases. Conclusion Physical functioning 
aspect on quality of life is better in SLE patients 
compared to SSc patients. However, mental 
aspect for both diseases are relatively similar.  
Keywords : systemic lupus erythematosus, 
systemic sclerosis, quality of life.  
 
 
Introduction 
Rheumatic diseases encompass a diverse group of 
over 100 autoimmune and chronic degenerative 
conditions that are linked with persistent, recurrent, or 
even lifelong pain and impaired physical function.1 
Musculoskeletal conditions provoke more functional 
limitations in the adult population in most developed 
nations than any other group of disorders. They are the 
major cause of years of living with disability all 
around the world and economies.1 The burden of 
rheumatic diseases is overwhelming and continuously 
expanding that coping with them will affect a wide 
spectrum 
 
of physical and psychological functions,2 which 
eventually impair quality of life.  
Quality of life (QoL) is a subjective, diverse 
concept of well-being correlated with a number of 
factors, such as severity and duration of illness, use 
of medications, and stress events.3 The subjective 
perception of QoL is now considered of great 
importance to assess the outcomes in a chronic 
disease, and has become central to evaluate the 
effectiveness of treatments as well.3 With no 
exception, this also occurs in systemic lupus 
erythematosus (SLE) and systemic sclerosis (SSc). 
They are multiorgan diseases that have a 
heterogeneous physiologic and biologic changes, 
unpredictable disease course, and many 
comorbidities which can decrease patients’ 
physical activity, which eventually affecting the 
health-related QoL.  
There are many studies evaluating QoL of SLE 
and SSc individually.2-6 However, there are only a 
few studies comparing their findings between both 
of them.6, 7 This study aims to compare the quality 
of life on SLE and SSc patients. 
 
Method 
This study was a cross-sectional study and 
conducted in rheumatology outpatient clinic of 
Hasan Sadikin Hospital Bandung, Indonesia from 
January 2015 until March 2017. The respondents 
were patients diagnosed as SLE and SSc who 
undergo routine follow-up at rheumatology 
outpatient clinic. Respondents were asked to 
complete the Short Form-36 (SF-36), which is a 
comprehensive, general health survey with 
physical and mental health components.8 It 
consisted of 8 domains: physical functioning, 
physical role functioning, bodily pain, general 
health, vitality, social role functioning, emotional 
role functioning, and mental health. SF-36 has been 
validated as a quality-of-life measure in SLE, SSc, 
and many other rheumatic diseases.9, 10  
The inclusion criteria were 1) respondents who 
were at least 18 years old, and 2) fully completed the 
SF-36 questionnaire. Respondents with other chronic 
and severe comorbid diseases, such as malignancy, 
diabetes mellitus, and heart failure, would be 
dismissed as an exclusion criteria, as those described 
above may significantly be accounted 
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for the impaired health-related QoL of the patients. Baseline 
characteristics, including age, gender and duration of disease, 
were also collected during the visit. The Mann-Whitney U test 
was used to analyse the comparison. This study also has been 
approved by Hasan Sadikin General Hospital Ethics and 
Research Committee. 
 
Result 
There were 242 patients who completed the SF-36 
questionnaires. One hundred and ninety-three of them were SLE 
patients and forty-nine were SSc patients (see Table 1). The 
proportion of female patients was similar across two groups, 
which was more than 95%. Patients with SLE were slightly 
younger, with a mean age of 34.9 year, and had a longer duration 
of disease, with a median of 60 months. The highest proportion 
was found on the 21-30 years old age group on SLE patients 
(34.1%), meanwhile on SSc patients the 31-40 years old age 
group was the highest proportion (36.7%).  
The mean of physical component summary (PCS) score 
was significantly higher on SLE patients compared to SSc 
patients, which was about 40.6 vs 40.4 with p = 0.0001 (see 
Table 2). Meanwhile, the mean of mental component 
summary (MCS) score was similar among SLE and SSc 
patients (p=0.103). Almost all domains of SF-36 scores on 
SLE patients were significantly better than SSc patients (p < 
0.05 , see Figure 1), except for vitality (VT) and mental health 
(MH).  
However, there were not any significant differences (p-
value > 0.005) between PCS and MCS scores among limited 
and diffuse types of SSc (see Table 3). 
 
Table 1. Demographics SLE and SSc Patients   
Characteristics 
SLE*  SSc ** 
(n = 193) (n = 49)  
Sex: Female (%) 185 (95.8) 47 (95.9) 
Age: years (Mean) 34.9 39.7 
Age group     
≤ 20 (%) 7 (3.6) 2 (4.1) 
21-30 (%) 66 (34.1) 8 (16.3) 
31-40 (%) 64 (33.1) 18 (36.7) 
41-50 (%) 42 (21.8) 15 (30.6) 
≥ 51(%) 18 (9.3) 6 (12.2) 
Duration: months 60 (47-145) 36 (47-145) 
(Median (range))     
 
* Systemic Lupus Erythematosus  
** Systemic Sclerosis 
 
Table 2. Comparison of Quality of Life SLE and SSc Patients   
Variables SLE† (n=193) SSc‡ (n=49) P value 
    
PCS§ (mean) 40.6 40.4 0.0001* 
MCS¶ (mean) 42.2 42.2 0.103* 
     
*p-value analysis was done by Mann-Whitney U Test.  
†Systemic lupus erythematosus  
‡Systemic sclerosis  
§Physical Component Summary  
¶ Mental Component Summary 
 
 
Table 3. Comparison of Quality of Life between Limited 
and Diffuse SSc  
Outcome measure Limited (n=28) Diffuse (n=21) p-value 
Mean PCS†  40.9 39.8 0.64 
Mean MCS‡ 41.3 43.4 0.54 
 
†Physical Component Summary  
‡Mental Component Summary  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Web Diagram of 8 components of Quality of Life 
 
 
Physical Functioning (PF), Physical Role Functioning (RP), Bodily Pain 
(BP), General Health Perception (GH), Vitality (VT), Social Role 
Functioning (SF), Emotional Role Functioning (RE), and Mental Health 
(MH), Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc). 
Bold: SLE patients have significantly better score than SSc 
patients on this domain 
 
Discussion 
Patients with autoimmune rheumatic diseases share the same 
factors which probably influence their quality of life, such as 
chronic inflammation, pain, physical disability, anxiety and 
depression. It appears that overcoming rheumatic diseases 
affects an extensive spectrum of physical and psychological 
functions.2 Health-related QoL (HRQOL) of patients with 
SLE was significantly worse in all scales domains at an earlier 
age in comparison to both healthy individual and patients of 
some other common chronic diseases, such as hypertension, 
diabetes, and myocardial infarction.4,5,7 Similar with SLE 
patients, all the SF-36 subscale scores of SSc patients were 
lower than those in general population.3 
 
Physical aspect of quality of life 
This study showed that SLE patients had better physical 
components of QoL compared to SSc. This finding is similar to 
that reported in previous studies.6,7 The SF-36 score for PCS was 
lower in systemic sclerosis compared to SLE patients but not 
significantly (31.8 ±13.2 vs 39.0 ± 13.0 ).7 This might be 
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due to several reasons. First, SSc patients have greater 
physical disability than those with SLE. Earlier studies had 
measured physical disability among SSc and SLE patients 
using the disability section of the Health Assessment 
Questionnaire (HAQ) scores. In patients with systemic lupus 
erythematosus, the score was 0.66.11 Meanwhile, the disability 
index of patients with systemic sclerosis was found to be 0.92, 
which was higher than those with systemic lupus 
erythematosus. Disability subsequently has a significant 
influence on psychosocial adjustment and may influence the 
QoL of these patients.6 However, disability has largely been 
attributed to major internal organ involvement, Raynaud’s 
Phenomenon, or limitation in range of motion resulted from 
skin tightening, in patient with SSc, especially the diffuse 
type.7 Therefore, one may assume that the QoL as assessed by 
the SF-36 appeared to be related to the burden of clinical 
manifestation, such as the number of clinical involvements, 
the functional disability, and the pain.3  
The other contributing factors that may support the finding in 
this study is the prognosis of SSc itself that is poorer than SLE. 
The survival rates of SLE were 94% and 89% respectively at 5 
and 10 years12, meanwhile survival rates of SSc were only 74.9% 
at 5 years and 62.5% at 10 years.13 The lack of knowledge 
regarding the disease in conjunction with the facts that there are 
no definitive cure for both diseases make the appropriate pain 
management and any other treatments to slow down the 
progression of diseases are crucial in improving the physical 
health to increase QoL on both diseases. The implementation of 
effective treatment and the better knowledge of SLE within 
society may cause the better survival rate and lead to 
improvement of quality of life.  
However, as survival of both sufferers improves, the 
burden placed upon SLE and SSc patients has also increased. 
The economic burden of SLE is twofold greater than normal 
population, encompassing both the cost of treatment itself and 
the productivity losses caused by the disease.14 Eventually, the 
increasing burden of diseases will lead to the worsening of 
QoL. Disease activity along with poor mental and physical 
health, were repeatedly reported to be related to disease status, 
and it is therefore logical that their worsening would be 
associated with the increasing disease burden, such as costs.14 
As there is currently no definitive therapy for both diseases, 
treatments that are able to improve the disease flares and delay 
its progression are necessary in order to reduce the burden and 
improving QoL.14 Therefore, it is important to quantify costs, 
especially in an unpredictable and chronic autoimmune 
diseases.14  
The result of this study is in contrast with the study from 
Austria.15 They stated that patients with SLE had lower mean 
scores than SSc patients for QoL in all 8 domains, except for 
bodily pain and emotional role. Differences of total number of 
patients and respective ratio of localized and diffuse types of 
SSc could explain the different findings on this study. 
 
Mental aspect of quality of life 
The MCS on both groups were not significantly different. This 
might be due to the stigmatization of rash in SLE, tightening of 
the skin in SSc, the unpredictable course of the disease, 
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fatigue, environmental factors such as sun exposure and cold 
weather in both SLE and SSc, and lastly, the reduced life 
expectancy on both diseases that are influencing both of the 
diseases’ QoL.15 This might also explain why the comparison 
of mental health score of SF-36 on this study was not 
significantly different. 
 
Limited vs diffuse systemic sclerosis 
This study found that there were not any significant differences 
on quality of life in SSc patients based on their type of SSc. This 
is in contrast with other studies which stated that SSc patients 
with diffuse type had lower SF-36 scores or had greater disability 
index than the limited type; thus, representing the lower quality 
of life that SSc with diffuse type have.3,6,7 They stated that patients 
with diffuse type suffered more disability than the limited type 
because of the extension of the diffuse type, which eventually 
resulted in more impaired QoL. Although these findings may be 
due to the fact that Johnson, et. al. in their study collected a 
greater proportion of diffuse type subjects than the limited type, 
which influenced their PCS score and physical functioning on the 
SF-36.  
The importance of this study is to add knowledge about the 
impact of SLE and SSc on patients’ HRQOL. Healthcare 
providers should begin to focus on quality of life outcomes of 
SLE and SSc diseases by incorporating self-administered 
questionnaire, such as SF-36, in their evaluation of treatment. 
Clinical practice should accentuate an interdisciplinary approach 
to SSc patients involving doctors, physical and occupational 
therapists, psychologists, social workers, and spiritual leaders.15 
Since the physical ability of SLE and SSc patients are impaired, 
it might also affect their activities of daily living, as well as social 
and professional skills. Therefore, the refinement of QoL may 
also eventually improve the lives of their caretakers, community 
resources, and society.  
Another thing that must be highlighted is that health-
related QoL is affected by many other predictors beside the 
characteristics of the disease itself. Knowledge of these factors 
is, therefore, important in order to optimize treatment towards 
a multidisciplinary approach targeting on those related 
prognostics factors, which will eventually lead to the 
improvement of patients’ health-related QoL and well-being.2 
A subsequent study in the future regarding predictors of 
quality of life in SLE and SSc patients will be very much 
helpful to improve each of their QoL. 
 
Limitation of study 
Limitation of this study was the unavailability of data regarding 
each patients’ medications. Selection and compliance of 
medication used by patients may affect the outcomes of the 
diseases, and therefore, may result in the improvement of QoL. 
However, all of SLE and SSc patients in this study are still 
receiving corticosteroids and immunosuppressant or cytostatic 
agents as their main treatment. Another limitation was the 
promptness of management on their treatment was not identical 
in every patient; hence, it will affect the outcome and also the 
QoL. Lastly, the disease activity and severity of both SLE and 
SSc were not incorporated in the baseline characteristics of this 
study, which potentially influence the 
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QoL of both diseases, further study should be done 
to evaluate this. 
 
Conclusion 
Physical functioning aspect on quality of life is 
better in SLE patients compared to SSc patients. 
However, mental aspect for both diseases are 
relatively similar. Since SSc is not a common 
disease, there is a lack of awareness on the part of 
healthcare providers and policy makers.15 This is 
unfavorable for the sufferers since their QoL is 
lower than SLE patients as shown in this study. 
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